NeuroBo Completes Enrollment in Liver Disease Trial

NeuroBo Pharmaceuticals (Nasdaq: NRBO) has completed enrollment of patients in Part 1 of its two-part, Phase 2a clinical trial evaluating the efficacy and safety of DA-1241 for the treatment of metabolic dysfunction-associated steatohepatitis (MASH). Approximately 49 patients with presumed MASH have been randomized into this part of the study.

Earlier this month, the company received Safety Review Committee (SRC) approval of its trial, which allowed the company to continue without modification following a blinded safety review of the first six months of study conduct. NeuroBo anticipates delivering a full data readout from the trial in the second half of 2024.

Hyung Heon Kim, President and Chief Executive Officer of NeuroBo commented, “Enrollment of the final patient in Part 1 our Phase 2a clinical trial of DA-1241, in patients with presumed MASH, is another important event in the clinical development of our cardiometabolic assets. Based on the preclinical and clinical evidence to date, we believe that the unique mechanism of action of this promising cardiometabolic asset, targeting the inflammation associated with MASH, will translate into a safe and effective treatment for this disease. We look forward to reporting the full trial data expected in the second half of this year.”

In preclinical studies, DA-1241 demonstrated that GPR-119 agonists promote the release of the key gut peptides GLP-1, GIP, and PYY, which have a beneficial effect on liver inflammation, lipid metabolism, weight loss, and glucose metabolism. DA-1241’s therapeutic potential has been demonstrated in multiple preclinical animal models of MASH.

About NeuroBo Pharmaceuticals
NeuroBo Pharmaceuticals, Inc. is a clinical-stage biotechnology company focused on transforming cardiometabolic diseases. The company is currently developing DA-1241 for the treatment of Metabolic Dysfunction-Associated Steatohepatitis (MASH) and Type 2 Diabetes Mellitus (T2DM), and is developing DA-1726 for the treatment of obesity. DA-1241 is a novel G-protein-coupled receptor 119 (GPR119) agonist that promotes the release of key gut peptides GLP-1, GIP, and PYY. In preclinical studies, DA-1241 demonstrated a positive effect on liver inflammation, lipid metabolism, weight loss, and glucose metabolism, reducing hepatic steatosis, hepatic inflammation, and liver fibrosis, while also improving glucose control. DA-1726 is a novel oxyntomodulin (OXM) analogue that functions as a glucagon-like peptide-1 receptor (GLP1R) and glucagon receptor (GCGR) dual agonist. OXM is a naturally-occurring gut hormone that activates GLP1R and GCGR, thereby decreasing food intake while increasing energy expenditure, thus potentially resulting in superior body weight loss compared to selective GLP1R agonists. For more information, please visit www.neurobopharma.com.

Share This Article

 

About the Author

NeuroBo Completes Enrollment in Liver Disease Trial

Catie Corcoran

Biotech Editor